Oncology Other denied for missing prior authorization by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS Requires Prior Authorization for Oncology Drugs and How to Appeal

Blue Cross Blue Shield requires prior authorization (PA) for most oncology medications. PA serves as the plan's mechanism to verify that the drug, indication, and clinical circumstances meet its coverage criteria before dispensing. A "prior auth required" denial can mean the PA was never submitted, was submitted with insufficient clinical information, or was denied outright because the plan's review determined the criteria were not met. Understanding which situation you face is the first step in determining how to respond.

### Why This Denial Is Appealable

If the PA was denied, you have full internal appeal and external review rights — the PA denial is a coverage decision. If the PA was never submitted or was administratively incomplete, work with your oncologist's office to resubmit with complete documentation before filing a formal appeal. A denial based on a complete, properly documented PA request that is still refused is the strongest candidate for formal appeal.

### Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your denial notice. Under ERISA §503 full-and-fair review, you are entitled to see all information the plan relied upon and to submit additional clinical evidence not included in the original PA.
• External review (ACA §2719): If the internal appeal is denied, request independent external review within the four-month window from the final internal denial. An independent review organization, not BCBS, makes the binding decision.
• Expedited review: Oncology treatment delays are often clinically significant. Request expedited appeal and expedited external review if a standard timeline would jeopardize your health. Expedited external review typically resolves within 72 hours.

### Documentation to Gather

1. BCBS PA criteria for the specific drug: Request the written PA criteria and medical policy. Your appeal must address each criterion individually. 2. Diagnosis, staging, and biomarker records: Pathology reports, imaging, genomic or biomarker testing results, and other records that establish the precise clinical indication. 3. Prior-treatment line history: A chronological summary of all prior oncology therapies, with dates, regimens, best response achieved, and reason for discontinuation — to satisfy any step-therapy or prior-treatment requirements. 4. Prescriber medical-necessity letter: A detailed letter from your oncologist addressing each PA criterion with specific clinical findings from your chart. 5. Guideline concordance statement: Your oncologist should note that the proposed treatment aligns with recognized oncology guideline organization recommendations for your cancer type and stage.

### Criteria-Mapping Approach

| BCBS PA Criterion | Chart Evidence | |---|---| | Confirmed cancer diagnosis and histology | [Pathology report] | | Disease stage / extent | [Staging workup] | | Biomarker / molecular eligibility (if required) | [Test result and date] | | Prior treatment line(s) (if required) | [Each regimen, dates, outcome] | | Treatment is guideline-concordant | [Oncologist letter, guideline org reference] |

The single most important factor in a PA appeal is the oncologist's letter. A letter that maps each plan criterion to a specific chart fact — rather than providing a general clinical narrative — gives the reviewer everything needed to approve without further back-and-forth.